MA-BIAL/LYSOSOMAL
1.10.2020 13:02:10 CEST | Business Wire | Press release
BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced today that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This new research center focused on genetically-defined Parkinson’s disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005323/en/
Simultaneously, BIAL announced that it has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics Inc. (LTI) and taken on the entire R&D team.
António Portela, executive president of BIAL, reveals: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programs from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide. The development of this new research center in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine. ”
This acquisition not only provides the company with a pipeline of new product candidates in Parkinson’s disease but also an experienced R&D team, led by Peter Lansbury, professor of neurology at Harvard Medical School and a recognized thought leader in the field of neurodegenerative diseases.
With this acquisition, BIAL is expanding its pipeline, namely with the integration of new compounds in neurodegeneration already in clinical development, specifically for Parkinson's disease, where the pharmaceutical company already has a significant market position.
The executive president of BIAL also points out: “The compounds we’ve acquired are based on genetics, a new field of research for us. The lead asset, which now has the code name 'BIA 28-6156/LTI-291', has an innovative mechanism of action and presents the potential of being a first disease-modifying therapy for a genetic subset of Parkinson’s disease. It has successfully completed a Phase I trial program and should be ready to start Phase II studies in 2021. We´re progressing from symptomatic treatment to an intervention in the mechanisms of the disease, which is very exciting for BIAL. ”
“We are happy to be part of BIAL and take the lead on the growth story in the US,” says Kees Been, former CEO of LTI and now CEO of BIAL Biotech. "With the commitment and resources of BIAL we will be able to accelerate our novel clinical and research programs as targeted and personalized treatment approaches for genetically-defined PD patients.”
“On behalf of the LTI shareholders, I want to express our enthusiastic endorsement of BIAL as a good home for the programs of LTI, ” said Clay B. Thorp, General Partner, Hatteras Venture Partners. “This deal is a perfect fit and we have great confidence that the team, with the resources and commitment of BIAL, will advance LTI-291 and the other compounds rapidly to patients to treat this debilitating form of Parkinson’s disease. ”
BIA 28-6156 / LTI-291 is a drug compound aimed at treating patients with GBA-Associated Parkinson’s diseases (GBA-PD) caused by an underlying mutation in the GBA1 gene. This genetic mutation affects approximately 10% to 15% of Parkinson’s disease patients (100,000-150,000 patients in the US) and is a validated risk factor that generally leads to an earlier age of disease onset and more rapid disease progression.
In addition to an upfront payment, the total value of the deal could reach up to 130 million dollars, based on attainment of a series of milestone payments as the assets progress through the clinic and into the market. Other financial terms will not be disclosed.
About BIAL Biotech
BIAL Biotech is a Center of Excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster. BIAL Biotech is a wholly owned subsidiary of BIAL, a pharmaceutical company based in Portugal with locations across Europe.
About BIAL
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide.
For more information on BIAL: www.bial.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005323/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa and Bridge Expand Collaboration, with Plans to Bring Stablecoin-Linked Cards to Over 100 Countries3.3.2026 13:00:00 CET | Press release
Collaboration deepens as Bridge’s stablecoin-linked card program gains global momentum Visa (NYSE:V), a global leader in digital payments, and Bridge, a leading stablecoin infrastructure platform and a Stripe company, today announced an expansion of their global card issuance product that they first unveiled in 2025. Bridge enables businesses and fintech developers to offer stablecoin-backed Visa cards. Now, through Bridge’s partnership with Lead Bank, these card transactions can be settled onchain with Visa. Since launching stablecoin-linked cards, developers using Bridge have rapidly begun offering these Visa cards across the world, enabling consumers to make everyday purchases from stablecoin balances at any of Visa’s 175M+ merchant locations. Bridge-enabled stablecoin-linked cards are now live in 18 countries, with planned expansion to over 100 countries across Europe, Asia Pacific, Africa and the Middle East by end of year. Popular crypto platforms like Phantom and MetaMask are us
AI Is Resetting the Rules of Growth in CPG3.3.2026 13:00:00 CET | Press release
NIQ and Kearney analysis finds challenger brands gaining share as AI reshapes innovation and product discovery NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released The New Growth Frontier. This new analysis, produced in collaboration with Kearney, reveals that artificial intelligence is reshaping how consumer packaged goods (CPG) brands innovate and compete—with profound effects on innovation, product discovery, and consumer path to purchase. Over the past three years, established niche brands increased US market share by 1.5 percentage points (2022–2025), while large and mid-size national brands declined by 2.1 percentage points, according to NIQ retail measurement data across all categories. This data signals a structural shift: Scale remains powerful, but scale is no longer destiny. Competitive advantage increasingly depends on agility, precision, and the ability to surface effectively in AI-mediated discovery environments. “We are entering a precision era
TestGorilla Launches New AI Readiness and AI Fluency Assessments to Help Companies Hire for the Skills That Matter Now3.3.2026 11:34:00 CET | Press release
Seven new AI assessments, built on TestGorilla's five-pillar AI Fluency Framework, give hiring teams a science-backed way to evaluate what resumes can no longer reveal. TestGorilla, the skills-based hiring platform trusted by thousands of organisations worldwide, today announced a suite of new assessments and simulation tests purpose-built to help talent acquisition teams evaluate AI readiness and AI fluency off the back of the company’s flagship event: Hire for the AI Era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303398545/en/ Use validated assessments and structured AI video interviews through the TestGorilla platform to measure different aspects of AI fluency across technical and non-technical roles. Inside the platform, tools are clearly labeled with AI fluency making it easy to find and build an assessment. The launch coincides with a crucial shift in the hiring landscape. TestGorilla co-founder and CEO Wouter
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance3.3.2026 11:19:00 CET | Press release
Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery. Unlike traditional Extended Depth of Focus lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL - while preserving contrast sensitivity, visual quality, and minimizing side effects such as halos and glare, hallmarks of its patented fully refractive design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303823337/en/ Swiss Advanced Vision premium IOL lenses for cataract surgery A recent peer-reviewed study, Comparative Analysis of Visual Outcomes Between Lucidis 108M (EDOF) and PhysIOL BVI FineVision (Diffractive) IOLs Using Defocus Curve Measurements by H. Naftali, W. Nasser, and M. Naftali, provides compelling comparative data. The findings show that Lucidis® achieves a d
Türk Telekom and P.I. Works Announce Strategic Collaboration on AI-Driven 5G Network Slicing at MWC Barcelona3.3.2026 10:16:00 CET | Press release
Türk Telekom and P.I. Works today announced a strategic collaboration on AI-driven 5G network slicing assurance, unveiled during GSMA Mobile World Congress (MWC) Barcelona 2026. Türk Telekom has successfully trialed P.I. Works’ AI-powered 5G RAN Slice Assurance solution in Türk Telekom R&D Innovation & Test Center, strengthening its ability to deliver differentiated and performance-assured 5G services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303543772/en/ The solution is designed to ensure network slicing performance by enabling real-time monitoring of slice-level KPIs, early detection of performance degradations, and AI-assisted root cause analysis. With these capabilities, Türk Telekom aims to proactively manage service levels, and ensure consistent service continuity across different 5G slice types. Türk Telekom Ebubekir Şahin stated: “As we approach the 5G era, we continuously evolve our mobile network to deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom